Market Cap 421.54M
Revenue (ttm) 31.08M
Net Income (ttm) -200.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -644.79%
Debt to Equity Ratio 0.47
Volume 2,888,400
Avg Vol 2,378,922
Day's Range N/A - N/A
Shares Out 363.40M
Stochastic %K 25%
Beta 0.71
Analysts Sell
Price Target $2.92

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its...

Industry: Biotechnology
Sector: Healthcare
Phone: 281 863 3000
Fax: 281 863 8088
Address:
2445 Technology Forest Boulevard, 11th Floor, The Woodlands, United States
humble_bob
humble_bob Feb. 4 at 1:20 AM
$LXRX it's too late, the damage is done. the damage is done. hopefully this finally just goes under in 2026. 2025 saw .30 pushing OTC delist fate awaiting crooks Mike and Ray assisting short hedge funds to extract $$'s of the sucker longs here. Not to mention their criminal salaries... this is a trap. I (Lonnel) have been laughing all the way to the bank everyday to get cash for the gentlemans club. BLTA!
1 · Reply
UofMAlum
UofMAlum Feb. 4 at 12:05 AM
$LXRX I don't trust a $0.07 drop in after hours just like I don't trust a $0.07 jump in after hours.
2 · Reply
gaslemoine
gaslemoine Feb. 3 at 10:03 PM
$LXRX I’ve been long on LXRX for over two years and I hold over 50,000 shares. I got in around $1.60, which is still roughly my average. So far, each earnings report has shown modest sales and continued high spending. Unless we see clear and strong new clinical data, the stock still feels more speculative than fundamentally driven.
2 · Reply
GenericPoster
GenericPoster Feb. 3 at 9:13 PM
$LXRX Loving the really strong close today with volume along with Monday’s strong action. So, congrats to all who bought last Friday, Monday or even earlier today although those who bought as it bounced off the 50 Day Moving Average Friday around $1.10 to $1.12 are up nearly 15% on those shares and we mostly keep our ownership percentage from the ~18% dilution with the secondary offering. I was banking on the underwriters wanting their customers buying this secondary to be underwater by much so figured this would get to at least $1.25 somewhat quickly. Besides, it was a huge vote of confidence that the majority owner and insider participated and bought half the offering as they know what is really happening. For reference, the $1.30 secondary offering price is 23.5% below the $1.70 higher close on January 27th.
0 · Reply
beezee8
beezee8 Feb. 3 at 9:13 PM
$LXRX Glad I added again today. With Friday's purchase, new shares average 1.17. Will look cheap in months to come
1 · Reply
SniperPro
SniperPro Feb. 3 at 9:09 PM
$LXRX THERE GOES A BIG BLOCK LOADED.... RAY & EXTON, IF YOU GET ON MY NERVES ONE MORE TIME, I’M MOVING INTO YOUR LIVING ROOM AND YOU’RE COOKING MY BREAKFAST... I DON’T PLAY GAMES... YEAH—LAUGH ALL YOU WANT. BOZOS LITTLE JOKE COST ME SEVEN FIGURES UNDERWATER, BUT I PLAY BY MY RULEZ TOO... NEW SHARES PRINTING GREEN!!!
1 · Reply
JonathanV
JonathanV Feb. 3 at 9:03 PM
$LXRX LF mutha’f’in’ G
0 · Reply
MYFLAUT
MYFLAUT Feb. 3 at 9:02 PM
$LXRX why the rise just beforebell
0 · Reply
hammarus
hammarus Feb. 3 at 9:02 PM
$LXRX Interesting close.
0 · Reply
cobragene
cobragene Feb. 3 at 9:01 PM
$LXRX Good Girl Lexi! :)
0 · Reply
Latest News on LXRX
Lexicon Announces Proposed Public Offering of Common Stock

Jan 29, 2026, 4:31 PM EST - 5 days ago

Lexicon Announces Proposed Public Offering of Common Stock


Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win

Nov 15, 2025, 6:46 AM EST - 2 months ago

Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win


Top 2 Health Care Stocks That May Crash This Month

Apr 25, 2025, 9:00 AM EDT - 10 months ago

Top 2 Health Care Stocks That May Crash This Month


Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal

Mar 28, 2025, 10:09 AM EDT - 11 months ago

Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal

NVO


humble_bob
humble_bob Feb. 4 at 1:20 AM
$LXRX it's too late, the damage is done. the damage is done. hopefully this finally just goes under in 2026. 2025 saw .30 pushing OTC delist fate awaiting crooks Mike and Ray assisting short hedge funds to extract $$'s of the sucker longs here. Not to mention their criminal salaries... this is a trap. I (Lonnel) have been laughing all the way to the bank everyday to get cash for the gentlemans club. BLTA!
1 · Reply
UofMAlum
UofMAlum Feb. 4 at 12:05 AM
$LXRX I don't trust a $0.07 drop in after hours just like I don't trust a $0.07 jump in after hours.
2 · Reply
gaslemoine
gaslemoine Feb. 3 at 10:03 PM
$LXRX I’ve been long on LXRX for over two years and I hold over 50,000 shares. I got in around $1.60, which is still roughly my average. So far, each earnings report has shown modest sales and continued high spending. Unless we see clear and strong new clinical data, the stock still feels more speculative than fundamentally driven.
2 · Reply
GenericPoster
GenericPoster Feb. 3 at 9:13 PM
$LXRX Loving the really strong close today with volume along with Monday’s strong action. So, congrats to all who bought last Friday, Monday or even earlier today although those who bought as it bounced off the 50 Day Moving Average Friday around $1.10 to $1.12 are up nearly 15% on those shares and we mostly keep our ownership percentage from the ~18% dilution with the secondary offering. I was banking on the underwriters wanting their customers buying this secondary to be underwater by much so figured this would get to at least $1.25 somewhat quickly. Besides, it was a huge vote of confidence that the majority owner and insider participated and bought half the offering as they know what is really happening. For reference, the $1.30 secondary offering price is 23.5% below the $1.70 higher close on January 27th.
0 · Reply
beezee8
beezee8 Feb. 3 at 9:13 PM
$LXRX Glad I added again today. With Friday's purchase, new shares average 1.17. Will look cheap in months to come
1 · Reply
SniperPro
SniperPro Feb. 3 at 9:09 PM
$LXRX THERE GOES A BIG BLOCK LOADED.... RAY & EXTON, IF YOU GET ON MY NERVES ONE MORE TIME, I’M MOVING INTO YOUR LIVING ROOM AND YOU’RE COOKING MY BREAKFAST... I DON’T PLAY GAMES... YEAH—LAUGH ALL YOU WANT. BOZOS LITTLE JOKE COST ME SEVEN FIGURES UNDERWATER, BUT I PLAY BY MY RULEZ TOO... NEW SHARES PRINTING GREEN!!!
1 · Reply
JonathanV
JonathanV Feb. 3 at 9:03 PM
$LXRX LF mutha’f’in’ G
0 · Reply
MYFLAUT
MYFLAUT Feb. 3 at 9:02 PM
$LXRX why the rise just beforebell
0 · Reply
hammarus
hammarus Feb. 3 at 9:02 PM
$LXRX Interesting close.
0 · Reply
cobragene
cobragene Feb. 3 at 9:01 PM
$LXRX Good Girl Lexi! :)
0 · Reply
cobragene
cobragene Feb. 3 at 8:26 PM
$LXRX Ok Lexi, lets close at the high, come on you can do it...
1 · Reply
ChrisBAB
ChrisBAB Feb. 3 at 8:21 PM
$LXRX Added more today
0 · Reply
ThunderCoopersmith
ThunderCoopersmith Feb. 3 at 6:29 PM
$LXRX I’m Shocked it held as well as it did with dilution.
1 · Reply
humble_bob
humble_bob Feb. 3 at 5:18 PM
$LXRX Shared feeling by all lxrx holders..
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Feb. 3 at 5:13 PM
$LXRX Another Bullish Article for us: https://www.bbc.com/news/articles/c5y2z2v964zo
0 · Reply
cobragene
cobragene Feb. 3 at 5:08 PM
$LXRX My confidence in Lexi, grows with the add'l millions INVUS/Ray keeps investing in Lexicon. Debbane didn't get his stellar WS reputation for being a dummy. (at least I don't think so)....
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Feb. 3 at 5:04 PM
$LXRX New Study good for $LXRX = READ THE SCREENSHOT FOR CONTINUATION. Bullish Pointers for $LXRX Pipeline (Driven by Excerpts) Bullish Point #1: Muscle Wasting in GLP-1s Validates Lexicon’s LX9851 (Obesity) Article Excerpt: "In 2024, a study in mice revealed that semaglutide can have a shrinking effect on a type of muscle specific to mammalian hearts. Other studies have also found significant skeletal muscle loss, along with the desired fat loss and anti-diabetic effects of this molecule." The $LXRX Thesis: This is the most critical excerpt. The medical community is waking up to the dangerous muscle-wasting side effects of GLP-1s (Ozempic/Wegovy). Lexicon’s LX9851 (which they licensed to Novo Nordisk in March 2025) is an oral ACSL5 inhibitor. It induces weight loss and activates the "ileal brake" (feeling full) without being an incretin (GLP-1). By sparing skeletal muscle, LX9851 solves the exact weakness of semaglutide highlighted in this article. https://www.sciencealert.com/semaglutide-pill-shows-heart-benefits-in-one-key-group-study-finds
0 · Reply
beezee8
beezee8 Feb. 3 at 4:39 PM
$LXRX I keep thinking of reasons NOT to add more, but am really struggling... Anything below 1.30, where majority holders are buying is a steal IMO. I've been long for years, so this isn't fake - would appreciate any reasons to hold out, thanks.
4 · Reply
gucag006
gucag006 Feb. 3 at 4:35 PM
$LXRX Interesting takes, quote (note the 24 mos runway): * The "Late Q4" FDA Head Start: Lexicon had their successful FDA meeting in Late 2025. They’ve known the "Phase 3 Green Light" details for 60+ days. That is more than enough time to have finalized a contract under a Confidential Disclosure Agreement (CDA). * The "War Chest" Raise: They didn't raise $94M because they were broke (they had $125M). They raised it because Big Pharma partners require a 24-month cash runwaybefore signing a global Phase 3 deal. It was a "Closing Condition." * The Underwriter Trap: Jefferies/Piper Sandler have a 30-day option to buy more shares at $1.30 that expires March 1. They must drive the price above $1.30 this month to get paid.
0 · Reply
MYFLAUT
MYFLAUT Feb. 3 at 4:25 PM
1 · Reply
selftaught
selftaught Feb. 3 at 4:05 PM
$LXRX we are fine here as long as we hold above the bottom line
0 · Reply
KurwaMac
KurwaMac Feb. 3 at 3:44 PM
$LXRX chances of BO in about a year?
0 · Reply